Lodenafil: ingredient and products

Key points

Lodenafil carbonate links two lodenafil units and acts as a prodrug.
Laboratory enzyme potency does not rank clinical benefit against Viagra or Cialis.
A 350-man phase III study showed benefit against placebo over four weeks.
The trial did not directly compare lodenafil with another active ED medicine.
Helleva’s Brazilian leaflet separates Cristália’s registration/production role from Supera RX’s commercial role.

A molecule with a detachable link

Think of the carbonate form as two units connected for delivery, with metabolism releasing the active part. A primary pharmacology study examined isolated human and rabbit erectile tissue, enzyme preparations, plasma stability and pharmacokinetics in dogs. It identified lodenafil as the active moiety after lodenafil carbonate administration.

In the laboratory enzyme preparation, the carbonate form inhibited cGMP breakdown more potently than the tested lodenafil and sildenafil. That finding concerns a particular assay and molecule. It does not demonstrate stronger erections, longer benefit or fewer adverse effects in patients. The researchers used several experimental systems; none substitutes for a head-to-head clinical treatment trial.

This distinction prevents a chemically interesting result becoming a “twice as strong” claim based merely on two linked units. The product’s labelled amount and formulation must still be read on their own terms.

What the phase III trial adds

A randomized, double-blind trial assigned 350 men with ED to placebo or lodenafil carbonate 40 or 80 mg for four weeks. Mean erectile-function questionnaire scores rose from 13.6 to 18.6 in the 40 mg group and from 13.4 to 20.6 in the 80 mg group, compared with 13.9 to 14.8 with placebo. Sexual-encounter measures also favoured active treatment.

At least one adverse event was reported by 28.7% with placebo, 40.9% with 40 mg and 49.5% with 80 mg. Nasal symptoms, headache, flushing, visual disturbance and dizziness occurred more often with active treatment. The results demonstrate a benefit-versus-placebo signal alongside tolerability costs; the higher amount should not be described as free extra efficacy.

Four weeks is a short observation period, and placebo was the comparator. The study does not establish superiority to sildenafil, tadalafil or vardenafil, or fully characterize uncommon long-term risks.

Match the ingredient to the Brazilian product

The Helleva professional leaflet identifies an 80 mg lodenafil carbonate tablet. Its legal section names Cristália as registrant and producer, and Supera RX Medicamentos as the commercial company. That explains why a Supera-branded pack and a Cristália development reference can both be relevant without being contradictory.

The leaflet also includes nitrate contraindications and cardiovascular precautions. Its PDE5 adverse-effect discussion should not be treated as an incidence estimate for every Helleva user; the controlled trial gives a more clearly defined population for the reported event rates.

A practical comparison

Lodenafil belongs in a global ingredient reference even when a reader’s local product options differ. The useful questions are whether the exact product is locally authorized, which formulation was prescribed, what evidence supports it, and whether its interaction profile fits the person’s medicines. Helleva is the specific product profiled below; this page does not infer worldwide availability from the Brazilian leaflet.

Products containing lodenafil

Lodenafil
Helleva (lodenafil)
Helleva is the original lodenafil carbonate brand from Cristália in Brazil. Learn what lodenafil is and how it was studied.